Over a 7-day studyperiod, the authors found that patients with COVID-19 had a higher incidence oftriglyceride concentrations >500 mg/dL (33% [n = 27] vs 4.3% [n = 23];P = 0.014).8 After correcting for differences in total propofol doses administered,COVID-19 was associated with an increased risk for developing hypertriglyceridemia(OR = 5.97; 95% CI: 1.16, 59.57; P = 0.031).8 Of note, patients with COVID-19 had a greater median BMI, baselinetriglyceride concentration, and multiple higher serum inflammatory markers (eg,C-reactive protein, procalcitonin). The gene discussed is CRP; the disease is COVID-19.